Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-06-18

A CANcer Development mOnitor

Descrizione del progetto


Heterogeneous Integration and take-up of of Key Enabling Technologies for Components and Systems

Through further development, integration and validation of micro-nano-bio and biophotonics systems from previous projects CanDo will develop an instrument that will permit the identification and concentration determination of rare cells in peripheral blood for two key societal challenges, early and low cost anti-cancer drug efficacy determination and cancer diagnosis/monitoring.A cellular link between the primary malignant tumor and the peripheral metastases, responsible for 90% of cancer-related deaths, has been established in the form of circulating tumor cells (CTCs) in peripheral blood. Furthermore the relatively short survival time of CTCs in peripheral blood means that their detection is indicative of tumor progression thereby providing in addition to a prognostic value an evaluation of therapeutic efficacy and early recognition of tumor progression in theranostics. In cancer patients however blood concentrations are very low (=1 CTC/1E9 cells) and current detection strategies are too insensitive, limiting use to prognosis of only those with advanced metastatic cancer. Similarly problems occur in therapeutics with anti-cancer drug development leading to lengthy and costly trials often preventing access to market. There is therefore a clear need for a novel analytical platform capable of highly reproducible and reliable identification of CTC concentrations of interest in an easily accessible format.With all relevant industrial stakeholders and users onboard CanDo is uniquely capable of delivering such a platform. Its novel cell separation/SERS analysis technologies plus nucleic acid based molecular characterization will provide an accurate CTC count with high throughput and high yield meeting both key societal challenges. Being beyond the state of art it will lead to substantial share gains not just in the high end markets of drug discovery and cancer diagnostics but due to modular technologies in others e.g. transport, security and safety and environment.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Invito a presentare proposte

FP7-ICT-2013-10
Vedi altri progetti per questo bando

Meccanismo di finanziamento

CP - Collaborative project (generic)

Coordinatore

UNIVERSITAT DE VALENCIA
Contributo UE
€ 501 501,00
Indirizzo
AVENIDA BLASCO IBANEZ 13
46010 Valencia
Spagna
Regione
Este Comunitat Valenciana Valencia/València
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partecipanti (9)